Sarepta Therapeutics (SRPT) Could Move 40% in the Next 30 Days on This Binary Event, Raymond James Reiterates Outperform
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated an Outperform rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) as the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
